Qatar committed to supporting WHO's mission to build a healthy future: Minister for Public Health
Tribune News Network
Geneva
Minister of Public Health His Excellency Mansoor bin Ebrahim Al Mahmoud has reaffirmed Qatar's steadfast commitment to supporting the World Health Organization (WHO) and its mission to build a healthier future, grounded in strong partnerships, a clear vision, and a firm dedication to the principles of justice, driven by the belief that health is both a goal and a means to achieve a more just, safe, and humane world.
In his speech at the ongoing World Health Assembly (WHA) meetings in Geneva, the minister said, 'Qatar believes that health is a cross-border issue.
'Through high-level strategic dialogue with the World Health Organization and support for its Fourteenth General Programme of Work, Qatar remains firmly committed to advancing the organisation's strategic objectives. This commitment is driven by the belief that collaborative action is the foundation for achieving health equity for all.'
He added, 'Qatar plays an active role in supporting global health security, promoting development, and providing humanitarian assistance to affected countries. This has been evident in Qatar's swift response to crises and its efforts to ensure equitable access to health resources in partnership with our regional and international partners.'
The minister explained that Qatar's third National Health Strategy (NHS3) is aligned with Qatar National Vision 2030 in its focus on achieving universal health coverage, promoting health equity, enhancing the patient experience, and improving the efficiency of the healthcare system.
He said, 'The humanitarian tragedy unfolding in the Gaza Strip for over a year and a half, as a result of Israeli aggression, calls for intensified efforts by the international community and international organisations to end this suffering and to uphold the fundamental human right to a dignified life and access to healthcare.'
The World Health Assembly is being held in Geneva, Switzerland, from May 19 to 27 under the theme 'One World for Health'.
The Qatari delegation is headed by the Minister of Public Health.
The assembly serves as the decision-making body of the World Health Organization.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Qatar Tribune
19 hours ago
- Qatar Tribune
Pakistan Healthcare Solutions Conference in Doha fosters bilateral collaboration
Tribune News Network Doha The Embassy of Pakistan in Qatar, in collaboration with Hamad Medical Corporation's (HMC) ITQAN Clinical Simulation and Innovation Centre, successfully hosted the Pakistan Healthcare Solutions Conference on June 2, at the ITQAN Clinical Simulation and Innovation Centre in Doha. The event, organised with the Atlantic International Business Network (AIBN) as the executive partner, aimed to advance a shared vision for healthcare innovation and strengthen Pakistan-Qatar collaboration. The conference was honoured by the presence of Federal Minister for National Health Services, Regulations and Coordination of Pakistan, Syed Mustafa Kamal, as the chief guest from Pakistan, and Assistant Minister for Health Affairs, Ministry of Public Health, Qatar, HE Dr. Salih Al Marri, as the chief guest from Qatar. Ali Al Janahi, HMC acting assistant managing director, Dr. Abdulla Ali Al-Ansari, medical advisor to the managing director of HMC, also attended, highlighting the high-level commitment to bilateral healthcare ties. The event brought together key stakeholders from the medical, pharmaceutical, telehealth, academic, and regulatory sectors of both nations. It provided a platform for government officials, healthcare leaders, innovators, and investors to explore opportunities for cross-border partnerships and advancements in healthcare development. The program commenced with inaugural addresses by Dean of Weill Cornell Medicine-Qatar, Javaid I. Sheikh, M.D., M.B.A., and the Executive Director of the ITQAN Clinical Simulation and Innovation Centre, Dr. Abdulla Ahmad. Their remarks underscored the transformative potential of collaborative efforts in strengthening healthcare systems between Pakistan and Qatar. Keynote presentations were delivered by Lt. Gen. Arshad Naseem HI (M), surgeon general of Pakistan, and Prof. Dr. Ambreen Afzal Ehsan, vice president of the College of Physicians and Surgeons Pakistan. These sessions highlighted Pakistan's advancements in healthcare and set the stage for discussions on bilateral cooperation. Two high-level panel discussions enriched the conference. The first, on Pakistan-Qatar R&D Collaboration, moderated by Rahid Mazhar, featured experts including Prof. Dr. Muhammad Yar, Dr. Ali Raza, Dr. Rayaz Malik, and Dr. Yousuf Al Maslamani. The second, on Emerging Smart Healthcare and Innovation Opportunities, moderated by Dr. Hasham Khan, included Dr. Fatih Mehmet Gul, Dr. Rola Hammoud, Dr. Zahid Ali, Dr. Javaid Sheikh, and Muhammad Irfan, focusing on innovative healthcare technologies. Additional presentations were delivered by Dr. Obaidullah Malik, CEO of the Drug Regulatory Authority of Pakistan (DRAP); Amr Metwally, assistant executive director at ITQAN; Ikram Ul Haq, president of the Sialkot Chamber of Commerce; Muhammad Irfan, CEO of Xeven Solutions; and Tanvir Khan, representing Labware Arabia. These talks showcased innovations in regulatory frameworks, medical technology, and industry partnerships. An exhibition featured stalls from leading companies such as Allison, Labware, and others, displaying advancements in medical devices, laboratory technologies, and AI-powered solutions. This interactive platform facilitated knowledge exchange and explored potential avenues for future collaboration. The conference concluded with remarks by Hafiz Muhammad Talha, CEO of AIBN and managing director of Metas Qatar, followed by a closing address by Ambassador of Pakistan to Qatar HE Muhammad Aamer. The ambassador reaffirmed the Embassy's commitment to fostering enduring healthcare partnerships between Pakistan and Qatar.
Qatar Tribune
19 hours ago
- Qatar Tribune
Gaza aid centres shut, access to area prohibited
Agencies Tel Aviv/Gaza Following reports that Israeli forces killed people near a food distribution site in Gaza, all aid centres in the enclave remained closed on Wednesday. Avichay Adraee, Arabic spokesman for the Israel Defense Forces, said on X that facilities would remain shut for 'renovation, organisation and efficiency improvement works,' citing the Gaza Humanitarian Foundation (GHF), which runs the aid operations. The military warned civilians to avoid approaching the centres, declaring the surrounding roads as combat zones. 'It is strictly prohibited to enter the distribution centre areas,' the spokesman added. The centres are expected to reopen on Thursday. The closure comes after the Hamas-run health ministry said Israeli troops opened fire on civilians near a distribution point on Tuesday, killing at least 27 people and wounding about 90. The GHF had launched its distribution network just over a week ago after Israel, under international pressure, allowed limited humanitarian access following nearly three months of blockade. Meanwhile, at least 95 Palestinians were killed and 440 injured in Israeli attacks across Gaza in the past 24 hours, said the enclave's Health Ministry. An Israeli aerial attack killed two people and injured others to the west of Khan Younis, reported the Wafa news agency. One of those killed is a 12-year-old boy, it said. Attack victims were rushed to the Kuwaiti Field Hospital in Khan Younis for treatment, said the agency. It came after two other children were killed earlier by an Israeli drone attack in southwestern Gaza City.
Qatar Tribune
2 days ago
- Qatar Tribune
‘New paediatric Hematopoietic Stem Cell Transplant Ward expands access to life-saving care for children'
Dr Iyabo Tinubu-Karch, CEO of Sidra Medicine, said: 'The opening of our new paediatric Hematopoietic Stem Cell Transplant Ward, the first of its kind in the country, marks a major step in expanding access to life-saving care for children in Qatar and the region. As the HSCT program grows, it will play a vital role in reducing the need for outbound referrals and in positioning Qatar as a center of excellence for pediatric cell and gene therapies. This is about building sustainable, high-quality care close to home for our patients and their families.' Prof. Ibrahim Janahi, Chief Medical Officer at Sidra Medicine, said: 'The launch of the HSCT Ward reflects our commitment to supporting the Qatar National Vision 2030. It strengthens the foundation of a knowledge-based economy by building national expertise in precision and regenerative medicine. Our goal is to ensure that every child in Qatar can access the best possible treatment, close to home and grounded in clinical excellence.' Managed by the Hematology and Oncology Division at Sidra Medicine, the new ward is designed exclusively for pediatric patients under the age of 18. It is divided into two main sections—one section for children undergoing HSCT and the other for patients with complex hematology-oncology diagnoses such as cancer, that require intensive chemotherapy and inpatient care. With an initial capacity of 20 beds, the new pediatric HSCT ward integrates cutting-edge infrastructure, including high-level isolation facilities that meet international infection control standards. It is scheduled to receive patients for autologous transplants in late June of 2025 with preparations underway to care for inpatient children who will undergo allogeneic transplants, at a later stage. Dr Ayman Saleh, Division Chief of Pediatric Hematology-Oncology & Hematopoietic Stem Cell Transplant at Sidra Medicine, said: 'Our HSCT program brings together key specialties to deliver advanced and curative care for children with complex conditions. With four autologous procedures successfully completed and plans underway to offer allogeneic transplants in the near future, we are building a strong foundation for pediatric cellular therapy in Qatar. This service is a testament to the pioneering and family-centered care and cure approach that we offer to all our patients.' In addition to treating patients with various blood diseases and cancers, the HSCT program at Sidra Medicine is the core part of its precision medicine strategy to facilitate genomic research programs for pediatric autoimmune disorders, genetic and rare diseases. Sidra Medicine's HSCT program is further enhanced by a Good Manufacturing Practice (GMP)-qualified laboratory team operating under the Advanced Cell Therapy Core (ACTC). The ACTC manages the processing and cryopreservation of hematopoietic stem cells and is currently working toward Sidra Medicine's qualification as a treatment center for Casgevy, a gene therapy for thalassemia and sickle cell disease. Dr Chiara Cugno, Director of the Advanced Cell Therapy Core and GMP Facility at Sidra Medicine said: 'Our GMP-qualified laboratory is a key enabler in delivering safe and effective cellular therapies. By maintaining the highest standards in cell processing and cryopreservation, we are supporting precision treatments for children with cancer, blood, and immunologic disorders. It is an essential part of ensuring every child receives the most personalized care possible.' All HSCT program services will be open to both local and international patients, with more than 50 children currently awaiting transplantation in Qatar. Future phases for the HSCT program include scaling allogeneic transplant capacity and introducing CAR-T cell and gene therapies. The HSCT program includes a multidisciplinary team of specialized physicians, apheresis-trained staff, dedicated HSCT nurses, and allied health professionals. The Sidra Medicine care team also involves experts in immunology, infectious diseases, radiology, psychology, pharmacy, nutrition, child life, and social work. The integrated approach ensures comprehensive and patient-centered care throughout the transplant journey. Before a transplant, every child will go through a detailed evaluation at Sidra Medicine's outpatient clinic to ensure they are ready for the procedure. Once admitted, the children will undergo conditioning chemotherapy to prepare their bodies for the stem cell infusion. They will then be monitored very closely during the aplasia phase, when their immune system is at its weakest. Most patients will stay at the hospital for about 30 to 40 days. Following discharge, they will continue their care through regular follow-ups in an outpatient setting. In addition to medical and nursing care, Sidra Medicine offers support services for patients and families, including social work, clinical nurse specialists, and case management. While formal support groups are under development, ongoing engagement with families is embedded throughout the care process.
